Group items tagged

The Council of the Pharmaceutical Society NI (PSNI) to remove the two-year requirement as a registered pharmacist to have an Independent Prescriber (IP) annotation on the pharmacy register in Northern Ireland. It has further endorsed that the two-year requirement for entry onto stand-alone pharmacist independent prescribing courses be removed and replaced with an assessment before admission, by course providers, based upon guidance provided by the regulator. In conjunction with the Department of Health, the PSNI will now work towards a further public consultation on the necessary legislative changes. Dr Jim Livingstone, president of the PSNI, said: "The Department of Health has set a clear direction which will see pharmacist independent prescribers becoming increasingly important in the delivery of pharmacy services in Northern Ireland. Our role is to protect the public, but we are clear that our regulatory objective should not be an unnecessary barrier to the development of the profession and enhanced services being provided to the public."

The UK Health Security Agency (UKHSA) has published the latest national surveillance data on antibiotic prescribing and resistance. The English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report showed an increase in antibiotic use in all settings (apart from dental) in 2022. According to the report, antibiotic prescribing rose by 8.4 per cent in 2022 compared with 2021, although the number remains below 2019 pre-pandemic levels. "There are many reasons behind the increase in prescribing, one of which is likely related to decreased immunity and exposure to infections during the COVID-19 pandemic that may have underpinned the increased transmission in co-circulating infections, namely: influenza (flu), respiratory syncytial virus (RSV) and group A streptococcus (GAS)," the report stated.

The Royal Pharmaceutical Society (RPS) has introduced a new comprehensive learning programme to support pharmacists in Wales to deliver the Pharmacy Independent Prescribing Service (PIPS). Developed in collaboration with Health Education and Improvement Wales (HEIW), the programme is designed to "equip pharmacists with the essential knowledge, skills, and confidence needed to provide excellent patient care." While the primary emphasis is on pharmacists operating within primary care settings, those from various practice settings are also encouraged to register and participate in the programme. Commenting on the collaboration with HEIW, Elen Jones, director for Wales at the Royal Pharmaceutical Society, said that it will empower pharmacists across the country to deliver high-quality prescribing services to local communities.

The recent data released by the NHS England revealed that in 2022/23 nearly 86 million antidepressant items were prescribed to around 8.6 million identified patients. According to the statistic published on 'Medicines Used in Mental Health' of the 5 British National Formulary (BNF) sections, 4 had increases in items and identified patients across 2022/23. The only BNF section to decrease since 2021/22 was hypnotics and anxiolytics. Items fell by 2% to 14 million and identified patients fell by 2 per cent to 1.9 million in 2022/23 The data also revealed that Prescribing of Central Nervous System (CNS) stimulants and drugs for ADHD increased by 32 per cent in adults over 18 and 12 per cent in children 17 and under. "2022/23 was the first time that more adult patients have been prescribed drugs from this section than child patients, in the time period covered by these statistics," said the report.

CDC Guidelines for Prescribing Opioids for Chronic Pain and Controlled Substance Reporting System. Discuss the Opioid crisis history and prescribing trends

CDC Guidelines for Prescribing Opioids for Chronic Pain and Controlled Substance Reporting System. Discuss the Opioid crisis history and prescribing trends

Wales launched the new electronic prescribing service (EPS) last week, with the country's first electronic prescription sent and dispensed on 17 November. The new service allows prescriptions to be sent digitally to a patient's nominated pharmacy, thus eliminating the need for paper forms. It is part of a wider plan to introduce digital medicines and e-prescribing in all hospitals and primary care in the country. Wellington Road Pharmacy and Lakeside Medical Centre in Rhyl became the first community pharmacy and GP practice to use the EPS, which is expected to be rolled out across Wales in January 2024.

The Pharmacists' Defence Association (PDA) says the pharmacy regulator should maintain a two-year post qualification eligibility criteria, in addition to the qualitative measures being introduced which would be in the best interest of patient safety, before a pharmacist is allowed to commence an IP course. The association was responding to an announcement by the GPhC's move to scrap the two year requirement for Independent Prescribing (IP) course. "The PDA accepts that the qualitative approach could mean greater individual consideration of potential IP course candidates and the two-year measure could have sometimes been a blunt tool. However, the PDA is already seeing cases of patient harm and allegations around fitness to practice arising from IP," the association said. The association also said that it supports individual pharmacists with near misses, as well as actual incidents, giving the organisation possibly the most comprehensive understanding of risk. Frontline pharmacists also recognise these issues and in a survey of over 1,000 pharmacists undertaken by the PDA in late 2021, of those who had 2+ years' experience of practice and who were already independent prescribers, 90 per cent said the qualifying period should be two years or more.

"Our main concerns are that the use of what they call an asynchronous supply, where the prescriber neither sees nor talks to the patient at the time they issue the prescription, does lay itself open to perhaps people getting hold of medication that they shouldn't," the Head of Policy, PDA said. The Pharmacists' Defence Association (PDA) engages in a critical conversation on BBC Radio 4's Woman's Hour, shedding light on the online prescribing of weight loss drugs and advocating for safer practices. The PDA's spokesperson, Head of Policy Alima Batchelor, emphasised the importance of adhering to professional guidelines to ensure patient safety and mitigate regulatory concerns. During the feature, the PDA highlighted the complexities and risks associated with online supply chains, stressing the necessity for direct clinical consultations and pharmacist involvement in medication management. ""There are guidelines and advice about verification within the DiCE guidance, but it doesn't go quite far enough for us. We are concerned when patients decline to allow the online prescriber to advise their GP of what they're taking," Batchelor highlighted.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for Dioralyte oral rehydration sachets. "Dioralyte oral rehydration sachets are expected to be in limited supply until late December 2022. St Mark's solution is available as an unlicensed special and can support an uplift in demand," said DHSC. "Kidderminster formula is available as an unlicensed special and can support a partial uplift in demand. As an alternative to the unlicensed specials, the individual components can be purchased from community pharmacies and supermarkets or prescribed, but there have been intermittent supply issues with glucose powder." Diluted apple juice has been reported to be a potential alternative to electrolyte maintenance fluids in children with mild gastroenteritis and minimal dehydration. If there is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems an EPS prescription for unlicensed St Mark's solution cannot be issued.

The General Pharmaceutical Council (GPhC) has raised concerns over the rising risks related to online pharmacy services. It revealed over 30 per cent of its open Fitness to Practise (FtP) cases were related to online pharmacy, which is disproportionate to the sector of the market that online services occupy. The regulator has advised pharmacists and pharmacy owners providing online services that they should "not work with online providers who try to circumvent the regulatory oversight put in place within the UK to ensure patient safety". In the past five months, the Council has imposed seven interim orders on the registration of pharmacists who have worked for or with online prescribing services - after identifying serious concerns with their practice. It said: "These pharmacists were working as pharmacist independent prescribers for online services or were dispensing medicines prescribed online. Some of these pharmacists were the Responsible Pharmacist (RP) or the Superintendent Pharmacist (SP)."

CDC Guidelines for Prescribing Opioids for Chronic Pain and Controlled Substance Reporting System. Discuss the Opioid crisis history and prescribing trends

The General Pharmaceutical Council (GPhC) has called for comments and views on the recently launched consultation on selecting the appropriate mode of consultation when assessing a person's needs by pharmacy professionals including pharmacist prescribers. The guidance note sets out what the pharmacy professional or prescriber, in agreement with the patient, needs to consider when selecting the mode of consultation - such as face-to-face; video-link, video-chat, or other online platforms; telephone and online questionnaires - best suited to gaining the information needed to deliver safe and effective pharmacy care. The principles outlined in the guidance apply to consultations undertaken in all pharmacy settings, including those undertaken by online pharmacy services providers. "Our plan is to include the contents of this guidance note in the document: 'In practice: Guidance for pharmacist prescribers' when we undertake our next review," said the regulator.

Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday announced that fluoroquinolone antibiotics must only be administered when no other antibiotics are appropriate for use. It elaborated that fluoroquinolones given systemically (by mouth, injection, or inhalation) should only be prescribed "when other recommended antibiotics have failed, will not work due to resistance, or are unsafe to use in an individual patient." Previous regulations on fluoroquinolones stated that this class of antibiotics should not be prescribed for mild to moderate or self-limiting infections, or non-bacterial conditions. Further restrictions have been introduced after receiving reports from patients who have experienced long-lasting or disabling reactions following use of fluoroquinolones, the MHRA revealed. Dr Alison Cave, MHRA Chief Safety Officer, said: "Patient safety is our top priority. We have listened to the experience of patients regarding long-lasting and potentially irreversible adverse reactions following use of fluoroquinolone antibiotics, in some cases prescribed for mild-to-moderate infections.

Are you unaware of the shocking truth about ‪‎Teens‬ being prescribed psychotropic ‪‎Drugs‬ without diagnosis in the US? Keep reading to learn more about teenage prescription drug use in the United States. Read our latest blog to find out!

Are you unaware of the shocking truth about ‪‎Teens‬ being prescribed psychotropic ‪‎Drugs‬ without diagnosis in the US? Keep reading to learn more about teenage prescription drug use in the United States. Read our latest blog to find out!

The NHS England has introduced a training programme for 1000 staff to broaden their community pharmacy roles, thereby improving patient access to services. Among them, 500 pharmacy staff will be trained to supervise pharmacists during prescription training, while the remaining 500 will provide support for various training, including pre and post-registration programmes for pharmacists and pharmacy technicians. According to the NHSE, pharmacist and pharmacy technician roles are rapidly evolving due to healthcare changes and increased demand for clinical services in community pharmacy. "There are 3,000 independent prescribing training spots available for 2023/24. Educational supervision is a crucial part of this to enable the ongoing transformation and skills development of the growing pharmacy workforce." The NHSE-funded training, scheduled to begin next month, will ensure that those involved in educational supervision, including Designated Supervisors (DSs), Pre-registration Trainee Pharmacy Technician education supervisors and Designated Prescribing Practitioners (DPPs), can effectively support learners.

The Royal Pharmaceutical Society (RPS) has backed a new framework from NHS England to reduce inappropriate prescribing of addiction-causing medicines. It believes that the new framework is a positive step towards improving patient care by supporting medicine reviews and shared decision making to help people reduce their use of medicines that are no longer providing much clinical benefit. The society has also welcomed investment in innovative approaches to supporting patients and urged all pharmacists to refer people to such schemes. Director for England at RPS, James Davies said: "Pharmacists are well-placed to help reduce inappropriate prescribing of high strength painkillers such as opioids and other addictive medicines. "Pharmacy teams can also often spot repeat purchases of over the counter medicines by patients so are well placed to intervene and give advice on the management of chronic pain. Whilst opioids can play an important part in helping people with chronic pain there has long been a need for alternative approaches that are safer and more effective for patients.

The Pharmacists' Defence Association (PDA) has urged the community pharmacies to complete a short survey on the availability of commonly prescribed medicines. PDA is hearing from members working in community pharmacy about challenges they are facing in fulfilling prescriptions for some of the most common medicines, including antibiotics. It wants to hear from pharmacists on the front line about their recent experiences. The association said: "Whilst at this time of year the incidence of infections and illnesses can be heightened, demand is seemingly higher than usual, and we would like to hear more about how this is impacting on you and the patients in your care,"

Nestled in the heart of a bustling high street and a housing estate, at Lincoln Pharmacy, part of Mildcare Ltd Group, in Tower Hamlets in London, the scene is a testament to resilience and innovation, where queues of people seek aid from a pharmacy technician stationed behind a glass window-a symbol of the enduring impact of the pandemic. Amidst the array of modern amenities at the pharmacy stands Atulkumar Patel, the proprietor and Independent Prescriber (IP) at Lincoln Pharmacy, whose vision has propelled the establishment into a beacon of progressive healthcare. Owner of two Pharmacies, Patel's team of 20 dispenses an average of 20,000 prescriptions monthly, maintaining an NHS/OTC split of 80/20. Recipient of the prestigious Independent Prescriber of the Year award at the Pharmacy Business Awards 2023, Patel reflects on the pivotal moment when his pharmacy pioneered the rollout of COVID-19 vaccine jabs within the community. "When doctors' doors closed, pharmacy was the only place where people could get help and care," Patel recounts, emphasising the pivotal role pharmacies played during the crisis. Patel's dedication during the pandemic extended beyond mere service provision; it was about showcasing the untapped potential of pharmacies.

Healthcare professionals in the UK are being advised to avoid prescribing the migraine and antiseizure medication topiramate, commonly known by the brand name Topamax, to women and girls unless they fulfil the requirements of a Pregnancy Prevention Programme. This guidance follows new safety measures introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) following a major safety review, which highlighted a potential increased risk of neurodevelopmental disabilities in children exposed to topiramate during pregnancy. The Commission on Human Medicines (CHM) evaluated studies that examined the risks associated with using topiramate during pregnancy. These studies indicated that children born to mothers who took topiramate during pregnancy had an approximately 2 to 3 times higher risk of intellectual disability, autism spectrum disorders, and attention deficit hyperactivity disorder. Based on CHM's recommendations, the MHRA now advises that topiramate should not be prescribed for treating epilepsy during pregnancy unless there is no suitable alternative.